MIST News and Press, Milestone Pharmaceuticals Inc. From 10/03/19

Milestone Pharmaceuticals (NASDAQ: MIST ) announces that the first patient has been enrolled in the Phase 3 NODE-303 study. More news on: Milestone Pharmaceuticals Inc., Healthcare stocks news, Read more ...

MONTREAL and CHARLOTTE, N.C. , Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced ...

Gainers:  VHC   +20.9% . AIMT   +9.9% . AOBC   +2.8% . RDFN   +5.1%.  DRNA   +4.1% . More news on: VirnetX Holding Corp, Aimmune Therapeutics, Inc., American Outdoor Brands Corporation, Stocks on the move, , News on ETFs Read more ...

Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development Canada NewsWire MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 MONTREAL and CHARLOTTE, N.C. , Sept. 10, 2019 /CNW/ -- Milestone ...

Milestone Pharmaceuticals ( MIST ) Q2 results : Revenues: $0; R&D Expense: $10.5M; SG&A: $1.6M; Net loss: ($13.7M); loss/share: ($1.04) (+91.8%); Quick Assets: $145.8M (+69.5%). More news on: Milestone Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, ...

- FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies - - NODE-301 trial upsized from 100 to 150 adjudicated PSVT events to satisfy EMA requirements; Company remains on track for topline readout in 1H20...

Milestone Pharmaceuticals to Host Mid-Year Update Conference Call Canada NewsWire MONTREAL and CHARLOTTE, N.C., Aug. 6, 2019 MONTREAL and CHARLOTTE, N.C. , Aug. 6, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutic...

RESEARCH TRIANGLE PARK, N.C. , July 16, 2019 /PRNewswire/ -- Pappas Capital, a leading investor in early-stage life sciences companies, today announced the promotion of Kyle Rasbach , PhD, PharmD to a Managing Partner of Pappas Ventures, the firm's venture capital business. In his new ro...

Very few drugs are available for the cardiovascular sector, and even fewer companies actually develop a specialty focus in this area. Milestone Pharmaceuticals ( MIST ) is one of them. The company has a pipeline focusing on CV diseases, and its lead candidate etripamil is in late stage trial t...

The following slide deck was published by Milestone Pharmaceuticals Inc. in conjunction with this Read more ...